A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Bristol-Myers Squibb
Bristol-Myers Squibb
National Cancer Institute (NCI)
7 Hills Pharma, LLC
Pfizer
ModernaTX, Inc.
Vivace Therapeutics, Inc
Bristol-Myers Squibb
Neonc Technologies, Inc.
Sanofi
Maastricht University Medical Center
University of Michigan Rogel Cancer Center
Abramson Cancer Center at Penn Medicine
Sarcoma Oncology Research Center, LLC
The Netherlands Cancer Institute
Vanderbilt-Ingram Cancer Center
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)